ORGO FY 2025 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$564M+17.0% YoY

Gross Profit

$415M73.6% margin

Operating Income

$56M10.0% margin

Net Income

$37M6.6% margin

EPS (Diluted)

$0.15

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$24M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$599M

Total Liabilities

$165M

Stockholders' Equity

$434M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$564M	$482M	+17.0%
Gross Profit	$415M	$366M	+13.3%
Operating Income	$56M	-$1M	+4494.8%
Net Income	$37M	$861,000	+4201.0%